Abstract
Coccidioidomycosis is a fungal infection endemic to geographically restricted areas of the southwestern United States, and its incidence is increasing within endemic areas. Coccidioidal meningitis, an infrequent but very severe form of coccidioidomycosis, is associated with significant mortality and morbidity. The diagnosis depends on the demonstration of coccidioidal antibody or positive culture, histopathology, or cytology in the presence of typical abnormalities of the cerebrospinal fluid. Central nervous system complications of this infection may include hydrocephalus, vasculitis, infarctions, or parenchymal abscesses. Many patients with coccidioidal meningitis can achieve remission of infection following treatment with triazole antifungal agents. However, first-line therapy with high-dose oral fluconazole is associated with a high incidence of relapse after drug discontinuation. This article summarizes the pathogenesis, epidemiology, clinical manifestations, diagnostic studies, and treatment of coccidioidal meningitis, and highlights new information regarding this devastating infection.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Laniado-Laborin R: Expanding understanding of epidemiology of coccidioidomycosis in the Western hemisphere. Ann N Y Acad Sci 2007, 1111:19–34.
Smith CE, Beard RR: Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am J Public Health Nations Health 1946, 36:1394–1402.
Crum NF, Lederman ER, Stafford CM, et al.: Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine 2004, 83:149–175.
Johnson R, Caldwell JW, Welch G: The great coccidioidomycosis epidemic: clinical features. In Proceedings of the Fifth International Conference on Coccidioidomycosis. Edited by Einstein HE, Catanzaro A. Bethesda, MD: National Foundation for Infectious Diseases; 1996:77–87.
Cox RA, Magee DM: Coccidioidomycosis: host response and vaccine development. Clin Microbial Rev 2004, 17:804–839.
Johnson RH, Einstein HE: Coccidioidal meningitis. Clin Infect Dis 2006, 42:103–107.
Kelly PC: Coccidioidal meningitis. In: Coccidioidomycosis: A Text. Edited by Stevens DA. New York: Plenum; 1980:163–193.
Mischel PS, Vinters HV: Coccidioidomycosis of the central nervous system: neuropathological and vasculopathic manifestations and clinical correlates. Clin Infect Dis 1995, 20:400–405.
Sunenshine RH, Anderson S, Erhart L, et al.: Public health surveillance for coccidioidomycosis in Arizona. Ann N Y Acad Sci 2007, 1111:96–102.
Arizona Department of Health Services: Infectious disease epidemiology. Available at http://azdhs.gov/phs/oids/epi/disease/cocci/index.htm. Accessed October 2008.
Vugia DJ, Wheeler C, Cummings KC, Karon A: Increase in Coccidioidomycosis—California, 2000–2007. MMWR Morb Mortal Wkly Rep 2009, 58:105–109.
Santelli AC, Blair JE, Roust LR: Coccidioidomycosis in patients with diabetes mellitus. Am J Med 2006, 119:964–969.
Vincent T, Galgiani JN, Huppert M, Salkin D: The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955–1958. Clin Infect Dis 1993, 16:247–254.
Arsura EL, Kilgore WB, Caldwell JW, et al.: Association between facial cutaneous coccidioidomycosis and meningitis. West J Med 1998, 169:13–16.
Banuelos AF, Williams PL, Johnson RH, et al.: Central nervous system abscesses due to Coccidioides species. Clin Infect Dis 1996, 22:240–250.
Winn W: Coccidioidal meningitis: a followup report. In: Coccidioidomycosis Symposium on Coccidioidomycosis. Edited by Ajello L. Phoenix: University of Arizona Press; 1967:55–61.
Arsura EL, Johnson R, Penrose J, et al.: Neuroimaging as a guide to predict outcomes for patients with coccidioidal meningitis. Clin Infect Dis 2005, 40:624–627.
Kelly PC, Sievers M, Thompson R, Echols C: Coccidioidal meningitis: results of treatment in 22 patients. In: Coccidioidomycosis, Current Clinical and Diagnostic Status. Edited by Ajello L. Miami: Symposia Specialists; 1977:239–251.
Hagman HM, Madnick EG, D’Agostino AN, et al.: Hyphal forms in the central nervous system of patients with coccidioidomycosis. Clin Infect Dis 2000, 30:349–353.
Kelly PC: Coccidioidal meningitis. In: Coccidioidomycosis: Proceedings of the Fifth International Conference on Coccidioidomycosis. Edited by Einstein HE, Catanzaro A. Bethesda, MD: National Foundation for Infectious Diseases; 1996:373–384.
Dewsnup DH, Galgiani JN, Graybill JR, et al.: Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996, 124:305–310.
Ragland AS, Arsura E, Ismail Y, Johnson R: Eosinophilic pleocytosis in coccidioidal meningitis: frequency and significance. Am J Med 1993, 95:254–257.
Meyer PR, Hui AN, Biddle M: Coccidioides immitis meningitis with arthroconidia in cerebrospinal fluid: report of the first case and review of the literature. Hum Pathol 1982, 13:1136–1138.
Zepeda MR, Kobayashi GK, Appleman MD, Navarro A: Coccidioides immitis presenting as a hyphal form in cerebrospinal fluid. J Natl Med Assoc 1998, 90:435–436.
Erly WK, Bellon RJ, Seeger JF, Carmody RF: MR imaging of acute coccidioidal meningitis. AJNR Am J Neuroradiol 1999, 20:509–514.
Wrobel CJ, Meyer S, Johnson RH, Hesselink JR: MR findings in acute and chronic coccidioidomycosis meningitis. AJNR Am J Neuroradiol 1992, 13:1241–1245.
Wrobel CJ, Chappell ET, Taylor W: Clinical presentation, radiological findings, and treatment results of coccidioidomycosis involving the spine: report on 23 cases. J Neurosurg 2001, 95:33–39.
Stevens DA, Shatsky SA: Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect 2001, 16:263–269.
Johnson RH, Einstein HE: Amphotericin B and coccidioidomycosis. Ann N Y Acad Sci 2007, 1111:434–441.
Capilla J, Clemons KV, Sobel RA, Stevens DA: Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother 2007, 60:673–676.
Clemons KV, Sobel RA, Williams PL, et al.: Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002, 46:2420–2426.
Stevens DA, Clemons KV: Azole therapy of clinical and experimental coccidioidomycosis. Ann N Y Acad Sci 2007, 1111:442–454.
Graybill JR, Stevens DA, Galgiani JN, et al.: Ketoconazole treatment of coccidioidal meningitis. Ann N Y Acad Sci 1988, 544:488–496.
Classen DC, Burke JP, Smith CB: Treatment of coccidioidal meningitis with fluconazole. J Infect Dis 1988, 158:903–904.
Galgiani JN, Catanzaro A, Cloud GA, et al.: Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med 1993, 119:28–35.
Tucker RM, Galgiani JN, Denning DW, et al.: Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis 1990, 12(Suppl 3):S380–S389.
Perez JA Jr, Johnson RH, Caldwell JW, et al.: Fluconazole therapy in coccidioidal meningitis maintained with intrathecal amphotericin B. Arch Intern Med 1995, 155:1665–1668.
Duswald KH, Penk A, Pittrow L: High-dose therapy with fluconazole > or = 800 mg day-1. Mycoses 1997, 40:267–277.
Tucker RM, Denning DW, Dupont B, Stevens DA: Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990, 112:108–112.
Kamberi P, Sobel RA, Clemons KV, et al.: A murine model of coccidioidal meningitis. J Infect Dis 2003, 187:453–460.
Kamberi P, Sobel RA, Clemons KV, et al.: Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. Antimicrob Agents Chemother 2007, 51:998–1003.
Antony SJ, Jurczyk P, Brumble L: Successful use of combination antifungal therapy in the treatment of coccidioides meningitis. J Natl Med Assoc 2006, 98:940–942.
Cortez KJ, Walsh TJ, Bennett JE: Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003, 36:1619–1622.
Crum-Cianflone NF: Voriconazole in combination with amphotericin B for salvage therapy of coccidioidomycosis: case report and review of the literature. Infect Dis Clin Pract 2007, 15:265–268.
Proia LA, Tenorio AR: Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004, 48:2341.
Aperis G, Mylonakis E: Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Invest Drugs 2006, 15:579–602.
Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH: Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008, 42:1429–1438.
Pitisuttithum P, Negroni R, Graybill JR, et al.: Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005, 56:745–755.
Williams PL: Vasculitic complications associated with coccidioidal meningitis. Semin Respir Infect 2001, 16:270–279.
Hsue G, Napier JT, Prince RA, et al.: Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother 2004, 54:292–294.
Galgiani JN, Ampel NM, Blair JE, et al.: Coccidioidomycosis. Clin Infect Dis 2005, 41:1217–1223.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blair, J.E. Coccidioidal meningitis: Update on epidemiology, clinical features, diagnosis, and management. Curr Infect Dis Rep 11, 289–295 (2009). https://doi.org/10.1007/s11908-009-0043-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11908-009-0043-1